|
|
Max
India Limited is a multi-business corporate, driven by the spirit of enterprise and focused on people and service oriented businesses. The Company’s vision is to be one of India’s most admired corporates for Service Excellence.
It ‘Protects Life’ through its Life Insurance subsidiary Max New York Life, a joint venture between Max India and New York Life, a Fortune 100 company; ‘Cares for Life’ through its Healthcare company, Max Healthcare, a subsidiary of Max India Limited; ‘Enhances Life’ through its Health Insurance company, Max Bupa Health Insurance, a joint venture between Max India and Bupa Finance Plc., UK which is set to launch after statutory approvals; and ‘Improves Life’ through its Clinical Research business, Max Neeman, a fully owned subsidiary of Max India. From its past, Max India continues its interest in manufacture of Speciality Products for the packaging industry.
Max India Group’s consolidated turnover for half year ended Sept 09 was Rs. 4166 crore. The consolidated operating revenue was Rs. 2543 Crore, a growth of 23% over the same period last year. The Group is on a high growth path, with over 700 offices across around 400 locations in the Country and with people strength of 100,000+ persons as on 30th Sept 2009.
|
|
|
Key Subsidiaries
|
| |
|
|
|
MAX NEW YORK LIFE (MNYL) is a joint venture between Max India Ltd. and New York Life, a Fortune 100 company. MNYL, incorporated in 2000, is one of India’s leading private life insurance companies. The Company offers both individual and group life insurance solutions. It has established a wide distribution network across India. Through its wide network of highly competent life insurance agent advisors and flexible product solutions, MNYL is creating a partnership for life with its customers in India to help them meet their life stage needs. |
|
|
|
| |
|
|
|
Max Healthcare (MHC) is the country's first comprehensive provider of standardized, seamless and world-class healthcare services. It is committed to the highest standards of medical and service excellence, patient care, scientific and medical education. MHC operates eight centers in Delhi & NCR, offering services in over 30 medical disciplines. MHC has state of the art tertiary care facilities at Saket in South Delhi, secondary care hospitals at Pitampura, Patparganj, Gurgaon and Noida and an out patient facility, the Max Medcentre and a Speciality centre focused on Eye and Dental care at Panchsheel Park.
The tertiary care hospitals at Saket include Max Devki Devi Heart & Vascular Institute, a Centre of Excellence in cardiac services and the Max Super Speciality Hospital, a super speciality facility in Orthopaedics & Joint Replacement, Neurosciences, Paediatrics, Obstetrics & Gynaecology, Aesthetic & Reconstructive Plastic Surgery and Internal Medicine. In addition, it has an Institute of Allied Medical Services where it provides General and Laparoscopic surgery, Urology, Eye & ENT, Nephrology, Dermatology, Department of Mental Health & Behavioural Sciences amongst others. MHC has collaboration with Singapore General Hospital in the areas of medical practices, nursing, paramedical, research and training.
|
| |
|
|
Max Neeman Medical International (MNMI) is a Clinical Research services provider offering services across the value chain of new drug development to a growing list of Pharmaceutical, Biotech and Clinical Research clients, in India and abroad. MNMI continues to focus on developing alliances with mid sized pharma and biotech companies to transition their drug development work to India. It has an employee base of 200 and five Regional offices in India & one business development office in USA. |
| |
|
|
Max Speciality Films (MSF) specializes in manufacturing of wide range of sophisticated barrier and packaging films. The BOPP division of MSF has an installed capacity of 29,000 tons per annum. MSF’s leather finishing foil business division manufactures a range of leather finishing and laminating foils. |
| |
|
|
|
Max Bupa Health Insurance Limited (MBHI), a joint venture between Max India and UK-based Bupa Group. It is on course to start operations in the next 3 months. The Company has put in place its top management team headed by its CEO, Dr. Damien Marmion. |
|
|
|